CSIR-HRDC hosts intensive workshop on AI-driven drug discovery for scientists

Three-day programme equips CSIR researchers with advanced AI tools, molecular docking insights, and biomolecular simulation expertise

Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology

The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets

Chiba University study flags allergy risk in high-binding antibody drugs

For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109

The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved

Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer

Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies

Enveric Biosciences bags key US patent for mental health drug

EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year